Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madeleine M Tilanus-Linthorst

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Lancet (London, England)|July 26, 2005
MARIBS studyMadeleine M Tilanus-Linthorst, Inge-Marie Obdeijn, Karina C M Bartels
Clinical Biochemistry|January 6, 2009
MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patientsAdrian Kruit, Madeleine M Tilanus-Linthorst, Joke G Boonstra, et al.
International Journal of Cancer|March 31, 2015
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)Sepideh Saadatmand, Inge-Marie Obdeijn, Emiel J Rutgers, et al.
International Journal of Cancer|May 3, 2014
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort studySepideh Saadatmand, Janet R Vos, Maartje J Hooning, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Lancet (London, England)|July 26, 2005
MARIBS studyMadeleine M Tilanus-Linthorst, Inge-Marie Obdeijn, Karina C M Bartels
Clinical Biochemistry|January 6, 2009
MUC1 568 A/G genotype-dependent cancer antigen 15-3 levels in breast cancer patientsAdrian Kruit, Madeleine M Tilanus-Linthorst, Joke G Boonstra, et al.
International Journal of Cancer|March 31, 2015
Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)Sepideh Saadatmand, Inge-Marie Obdeijn, Emiel J Rutgers, et al.
International Journal of Cancer|May 3, 2014
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort studySepideh Saadatmand, Janet R Vos, Maartje J Hooning, et al.
Pageof 1